关于山东华特达因健康股份有限公司 2024 年第一次临时股东大会的 法律意见书 山东博翰源律师事务所 关于山东华特达因健康股份有限公司 2024 年第一次临时股东大会的 法律意见书 济南市经十路 11001 号中国人寿大厦南楼 8 层 电话：+86 531 8266 5806 传真：+86 531 8570 0088 山东博翰源律师事务所 致：山东华特达因健康股份有限公司 根据《中华人民共和国证券法》《中华人民共和国公司法》及中国证券监督管 理委员会《上市公司股东大会规则》（以下简称"《股东大会规则》"）等相关法律、 法规、规范性文件和《山东华特达因健康股份有限公司章程》（以下简称"《公司章 程》"）的规定，山东博翰源律师事务所（以下简称"本所"）受山东华特达因健康 股份有限公司（以下简称"公司"）的委托，指派宿扬帆、张岳律师出席公司 2024 年第一次临时股东大会并就本次股东大会的召集与召开程序、出席会议人员资格、 表决程序及表决结果等出具法律意见。 为出具本法律意见书，本所律师审查了公司提供的有关本次股东大会各项议程 及相关文件，听取了公司董事会就有关事项所作的说明。 在审查有关文件的过程中，公司向本所律 ...

证券代码：000915 证券简称：华特达因 公告编号：2024-028 山东华特达因健康股份有限公司 2024 年第一次临时股东大会决议公告 特别提示 1．本次股东大会未出现否决议案的情形。 2．本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1．会议召开的时间：现场会议召开时间为 2024 年 8 月 20 日下 午 15:00；网络投票的时间为 2024 年 8 月 20 日，其中通过深圳证券 交易所交易系统投票的时间为 2024 年 8 月 20 日上午 9:15－9:25， 9:30－11:30，下午 13:00－15:00，通过深圳证券交易所互联网系统 （http://wltp.cninfo.com.cn）投票时间为 2024 年 8 月 20 日 09:15 至 2024 年 8 月 20 日 15:00 期间的任意时间。 2．现场会议召开地点：公司会议室。 6．会议的召集、召开符合有关法律、行政法规、部门规章、规 范性文件和《公司章程》的规定。 7．出席本次会议的股东及股东授权委托代表共 176 名，代表股 份 60,518,032 股，占公司有表决权股份总数的 25. ...

Investment Rating - The investment rating for the company is "Accumulate" [6] Core Views - The company has shown stable profit growth in H1 2024, with a revenue of 1.154 billion yuan, a year-on-year increase of 0.10%, and a net profit of 332 million yuan, up 3.12% year-on-year. The second quarter saw a revenue of 583 million yuan, a year-on-year decrease of 1.55% but a quarter-on-quarter increase of 1.89% [2][3] - The growth strategy for H2 2024 focuses on expanding the market for core products and new products through innovative marketing channels, which is expected to accelerate revenue and profit growth [2][3] Financial Performance - In H1 2024, the pharmaceutical segment generated 1.136 billion yuan in revenue, a 0.47% increase year-on-year, accounting for 98.42% of total revenue. The online channel revenue has shown significant growth [3] - The company aims for a 10% growth in revenue and net profit for the full year 2024, driven by marketing strategies and new promotional channels [3][5] Profitability - The net profit margin for H1 2024 was 27.60%, an increase of 1.36 percentage points year-on-year. The sales expense ratio decreased by 4.64%, contributing to the improved net profit margin [4] - The company expects stable gross margins and a high overall net profit margin for the year [4] Growth Forecast and Valuation - The company maintains its earnings per share (EPS) forecast for 2024-2026 at 2.85, 3.22, and 3.66 yuan per share, respectively. The PE ratio for 2024 is projected to be 9 times based on the closing price on August 2, 2024 [5][8] - The company is optimistic about the continued growth of its core product, "Yikexin," and key secondary products, which are expected to drive steady revenue growth [5]

1 合并资产负债表（续） | 编制单位：山东华特达因健康股份有限公司 | | 金额单位：人民币元 | | | --- | --- | --- | --- | | 项 目 | 注释 | 2024 年 6 月 30 日 | 2024 年 1 月 1 日 | | 流动负债： | | | | | 短期借款 | | | | | 交易性金融负债 | | | | | 应付票据 | | | | | 应付账款 | 五、20 | 28,279,622.34 | 32,190,726.47 | | 预收款项 | 五、21 | 1,807,227.13 | 401,479.48 | | 合同负债 | 五、22 | 74,623,022.25 | 108,840,188.56 | | 应付职工薪酬 | 五、23 | 202,149,698.41 | 173,681,277.11 | | 应交税费 | 五、24 | 87,421,471.60 | 74,603,500.61 | | 其他应付款 | 五、25 | 116,538,412.88 | 200,698,405.89 | | 其中： 应付利息 | | 2,041,425.00 | ...

公司将积极推进董事会、监事会换届的相关工作，预计将于 2025 年 2 月底前完成董事会、监事会及管理层换届。 山东华特达因健康股份有限公司董事会 2024 年 8 月 1 日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 山东华特达因健康股份有限公司（以下简称"公司"）第十届董 事会、监事会任期将于 2024 年 8 月 17 日届满。鉴于：1）本届董事 会聘任杨杰女士为公司职业经理人，担任公司总经理职务，聘期至 2024 年 12 月 31 日，董事会任期与职业经理人（总经理）任期不一 致。2）公司贯彻国企改革三年行动计划，实行经理层任期制和契约 化管理，国资对公司经理层的考核以会计年度为单位。董事会任期与 国资对公司经理层的考核期不一致。为理顺管理关系，进一步提高公 司规范运作水平和科学管理水平，使董事会任期与职业经理人（总经 理）任期以及与国资对经理层的考核期一致，公司董事会、监事会将 延期换届，董事会各专门委员会、公司高级管理人员的任期也相应顺 延。 在换届选举工作完成前，公司第十届董事会、监事会全体成员、 董事会各专门委员会成员、高级管理人员及证 ...

证券代码：000915 证券简称：华特达因 公告编号：2024-022 山东华特达因健康股份有限公司 第十届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 山东华特达因健康股份有限公司第十届董事会于 2024 年 7 月 19 日以电子邮件形式发出召开第十三次会议的通知，并于 2024 年 7 月 30 日在公司会议室召开会议。会议应参加董事 8 名，实际参加董事 8 名。会议由公司董事长朱效平先生主持。会议符合有关法律、法规、 规章和《公司章程》的规定。 二、董事会会议审议情况 （三）以 8 票同意 0 票弃权 0 票反对的表决结果，审议通过了 《公司 2024 年中期利润分配预案》： 公司 2024 年 1-6 月合并实现营业收入 1,154,413,477.20 元，利 润总额 748,423,285.19 元，母公司税后净利润 557,804,886.51 元， 加以前年度结转的未分配利润 889,490,272.02 元，减 2024 年 5 月分 配 2023 年度的现金股利 468,662,97 ...

2024 年半年度非经营性资金占用及其他关联资金往来情况汇总表 编制单位：山东华特达因健康股份有限公司 单位：元 山东华特达因健康股份有限公司 | | | | 上市公司核 | 2024 年 | 2024年 1-6月 | 2024 年 | 1-6 2024 | 年1-6月 | 2024 年 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公司 | 算的会计科 | 期初占 | 占用累计发 | 月占用资 | | 偿还累计发 | 6 月末 | 占用形成 | 占用性质 | | | | 的关联关系 | | 用资金 | 生金额（不含 | 金的利息 | | | 占用资 | 原因 | | | | | | 目 | | | | | 生金额 | | | | | | | | | 余额 | 利息） | （如有） | | | 金余额 | | | | 控股股东、实际控制人及 | | | | | | | | | | | | | 其附属企业 | | | | | | | | | ...

证券代码：000915 证券简称：华特达因 公告编号：2024-026 山东华特达因健康股份有限公司 关于召开2024年第一次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1.股东大会届次：2024 年第一次临时股东大会 2.会议召集人：公司董事会 3.会议召开的合法、合规性：董事会认为本次会议的召开符合有 关法律、行政法规、部门规章、规范性文件和《公司章程》的规定。 4.会议召开的日期、时间： 4.1 现场会议召开时间：2024 年 8 月 20 日下午 15:00 4.2 网络投票时间：2024 年 8 月 20 日 4.2.1 通过深圳证券交易所交易系统投票的时间为 2024 年 8 月 20 日上午 9:15－9:25， 9:30－11:30，下午 13:00－15:00； 4.2.2 通过深圳证券交易所互联网系统 (http://wltp.cninfo.com.cn) 投票时间为 2024 年 8 月 20 日 09:15 至 2024 年 8 月 20 日 15:00 期间 的任意时间。 5.会议的召开 ...

山东华特达因健康股份有限公司第十届监事会于 2024 年 7 月 19 日以电子邮件形式发出召开第十三次会议的通知，并于 2024 年 7 月 30 日在公司会议室召开会议。会议应参加监事 5 名，实际参加监事 5 名。会议由监事会主席王玲女士主持。会议符合有关法律、法规、规 章和《公司章程》的规定。 股票代码：000915 股票简称：华特达因 公告编号：2024-023 山东华特达因健康股份有限公司 第十届监事会第十三次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 二、监事会会议审议情况 （一）以 5 票同意 0 票弃权 0 票反对的表决结果，审议通过了《公 司 2024 年半年度报告》并发表如下审核意见： 经审核，监事会认为董事会编制和审议《公司 2024 年半年度报 告》的程序符合法律法规及深圳证券交易所规定的要求，报告内容真 实、准确、完整地反映了上市公司的实际情况，不存在任何虚假记载、 误导性陈述或者重大遗漏。 （二）以 5 票同意 0 票弃权 0 票反对的表决结果，审议通过了《关 于公司第十届董事会、监事会延 ...

Financial Performance - The company reported a total revenue of 6,630,326.70 RMB from government subsidies related to normal business operations[21]. - The company's operating revenue for the first half of 2024 was CNY 1,154,413,477.20, a slight increase of 0.10% compared to CNY 1,153,217,104.50 in the same period last year[36]. - Net profit attributable to shareholders was CNY 331,871,287.24, reflecting a growth of 3.12% from CNY 321,841,708.90 year-on-year[36]. - The net profit after deducting non-recurring gains and losses was CNY 318,600,238.56, up by 5.28% from CNY 302,626,154.93 in the previous year[36]. - The company's revenue for the reporting period was approximately CNY 1.15 billion, a slight increase of 0.10% compared to the previous year[53]. - The pharmaceutical segment generated revenue of CNY 1.136 billion, with a net profit of CNY 631 million, reflecting a year-on-year increase of 0.47% and 0.30% respectively[72]. - The company achieved a total revenue of CNY 1.154 billion in the reporting period, representing a year-on-year growth of 0.10%[72]. Non-Recurring Gains and Losses - The total non-recurring gains and losses amounted to 13,271,048.68 RMB after tax impacts and minority interests[21]. Research and Development - The company has maintained a strong commitment to R&D in children's health, enhancing its competitive edge[24]. - Research and development investment increased by 67.99% to approximately CNY 49.05 million, primarily due to an increase in R&D personnel[53]. - The company is focusing on the development of children's medications, supported by recent government policies aimed at enhancing the R&D and production of pediatric drugs[39]. - The company aims to launch 1 to 2 new pediatric drug varieties each year, enhancing its product matrix[4]. - The company plans to enhance its R&D efforts for new drugs, focusing on unique core technologies for children's medications, including innovative formulations and taste-masking techniques[99]. - The company has established a comprehensive children's drug product system through collaboration with universities and research institutions[50]. Market Position and Strategy - The company continues to lead the children's pharmaceutical industry in China, focusing on children's health products since 2007[24]. - The brand "Yikexin" remains the market leader in children's health products, with a significant market share[24]. - The company is actively pursuing market expansion strategies to strengthen its position in the children's healthcare sector[24]. - The company continues to lead the market with its flagship product, E-Care Vitamin AD, maintaining the highest market share in its category[4]. - The marketing strategy focuses on expert recommendations and convenient purchasing channels, adapting to market changes[49]. - The company has strengthened its marketing strategy, expanding the target age for its product "Yike Xin" to 0-18 years[72]. Financial Position - Total assets at the end of the reporting period were CNY 4,777,770,975.97, down 8.09% from CNY 5,198,294,479.89 at the end of the previous year[36]. - Net assets attributable to shareholders decreased by 4.59%, totaling CNY 2,845,093,487.55 compared to CNY 2,981,885,170.31 at the end of the last year[36]. - The total current assets decreased from 3,704,884,921.76 RMB to 3,304,920,737.19 RMB, a decline of approximately 10.8%[174]. - The total non-current assets decreased from 1,493,409,558.13 RMB to 1,472,850,238.78 RMB, a decline of about 1.4%[174]. - The total liabilities decreased from CNY 701,652,154.75 to CNY 623,386,969.58, a reduction of approximately 11.2%[196]. - Shareholders' equity decreased from CNY 4,496,642,325.14 to CNY 4,154,384,006.39, a decline of about 7.6%[196]. Cash Flow - The net cash flow from operating activities decreased by 29.43%, amounting to CNY 417,869,236.68 compared to CNY 592,107,241.53 in the same period last year[36]. - The net cash flow from investing activities increased by 177.21% to approximately $320.87 million, primarily due to the net redemption of structured deposits held by banks[54]. - The net cash flow from financing activities decreased by 40.10% to approximately -$973.08 million, mainly due to an increase in dividends paid[54]. - The net increase in cash and cash equivalents was approximately -$234.34 million, a 54.76% improvement compared to the previous period, influenced by the net redemption of structured deposits and increased dividends[54]. Compliance and Governance - The company has ensured compliance with all regulatory commitments and has no outstanding obligations as of the reporting date[26]. - The company has not reported any discrepancies between domestic and international accounting standards for the reporting period[19]. - The company is committed to enhancing its internal control systems and governance capabilities as part of its strategic focus on core pharmaceutical operations[72]. Environmental Responsibility - In the first half of 2024, Dain Pharmaceutical invested approximately 1.15 million in environmental governance and protection[119]. - During the reporting period, Dain Pharmaceutical's wastewater treatment system operated smoothly, with COD at 23.4 mg/L and ammonia nitrogen at 1.24 mg/L, both meeting the GB/T 31962-2015 standards[133]. - The company has implemented a self-monitoring plan for environmental protection, ensuring compliance with various environmental standards[119]. - Dain Pharmaceutical has actively participated in national public welfare activities, including the "Children's Safe Medication Science Community Tour" and "Height Management Free Clinic in Communities"[120]. - Dain Pharmaceutical has initiated the "AD Guardian Plan" to support children's growth and development through public welfare activities[120]. Legal and Administrative Matters - The company is involved in a lawsuit concerning the unauthorized use of its assets, with a claim amounting to 12.06 million[140]. - The company reported a total external guarantee amount of 134.51 million yuan, which accounts for 0.05% of the company's net assets[146]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[119]. - The company has not engaged in any significant related party transactions or asset acquisitions during the reporting period[128][129]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 19,270, with the largest shareholder, Shandong Huate Holding Group Co., Ltd., holding 22.00% of shares, totaling 51,544,340 shares[167]. - The company's total share capital as of June 30, 2024, is 234,331,485 shares, which serves as the basis for the upcoming dividend distribution[109]. - The company reported a cash dividend of 5 CNY per 10 shares, totaling 117,165,742.50 CNY, which represents 100% of the distributable profit[109].